Related Experiment Video

Updated: Feb 8, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

ALK inhibitors, resistance development, clinical trials

J M Rothenstein1, N Chooback2

  • 1RS McLaughlin Durham Regional Cancer Centre, Oshawa, and Department of Oncology, Queen's University, Kingston, ON.

Current Oncology (Toronto, Ont.)
|June 19, 2018
PubMed

Insights

Personalized medicine transformed advanced non-small-cell lung cancer (NSCLC) treatment. This review covers ALK-positive NSCLC therapies, clinical trials, and resistance, focusing on Canadian practices.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Advanced non-small-cell lung cancer (NSCLC) treatment has evolved significantly since the early 2000s.
  • Discovery of oncogenic drivers enabled personalized medicine and molecularly targeted therapies.
  • The identification of the ALK gene in NSCLC patients has spurred rapid development of targeted drugs.

Purpose of the Study:

  • To review the current treatment landscape for ALK-positive NSCLC.
  • To discuss available and emerging clinical trials for ALK-positive NSCLC.
  • To examine evolving clinical decision-making in ALK-positive NSCLC, with a focus on Canadian practice.

Main Methods:

  • Literature review of published studies and clinical trials.
  • Analysis of treatment outcomes and resistance patterns.
  • Focus on ALK-positive NSCLC and its management.

Main Results:

  • Several ALK-directed therapies are approved and more are in clinical trials.
  • Significant improvements in patient outcomes have been observed.
  • Emergence of resistance to ALK-targeted therapy is a critical challenge.

Conclusions:

  • ALK-positive NSCLC management requires ongoing research into optimal treatment strategies.
  • Understanding and overcoming treatment resistance is crucial for improving patient outcomes.
  • Canadian clinical practice is evolving in response to new therapeutic developments.
Keywords:
alectinibalk inhibitorsbrigatinibceritinibcns metastasescrizotinibnsclcresistance

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
1.5K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.6K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Trial and Error and Algorithm01:12

Trial and Error and Algorithm

A problem-solving strategy is a plan of action used to find a solution. Different strategies have distinct action plans. Trial and error involves trying different solutions until one works. For instance, to fix a broken printer, you might check ink levels, ensure the paper tray isn't jammed, and verify the printer's connection to your laptop. This method can be time-consuming but is commonly used. Thomas Edison, for example, used trial and error to find a suitable filament for the light...
425